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Abstract 
Background: Patients with type 2 diabetes (T2D) and coronary artery disease (CAD) have increased risk of cardiac 
dysfunction. The diabetic heart is characterized by increased fatty acid oxidation and reduced glucose uptake result-
ing in reduced cardiac efficiency. Glucagon-like peptide-1 (GLP-1) has shown to increase myocardial glucose uptake 
and to improve myocardial function. We examined the effect of the GLP-1 receptor agonist, liraglutide, on the systolic 
function of the left ventricle (LV) in patients with T2D and stable CAD.
Methods: In this placebo-controlled crossover study, 41 subjects with T2D and stable CAD were randomized to lira-
glutide or placebo and underwent dobutamine stress echocardiography (DSE) and exercise tolerance test at begin-
ning and end of each intervention. The primary endpoint was changes in LV ejection fraction. Secondary endpoints 
were exercise capacity and other measures of systolic function: wall motion score index (WMSI), global longitudinal 
strain (GLS) and strain rate (GLSR).
Results: Liraglutide, when compared to placebo, did not improve LV ejection fraction at rest (+0.54 %; 95 % CI 2.38–
3.45), at low stress (+0.03 %; 95 % CI 3.25–3.32), at peak stress (+1.12 %; 95 % CI 3.45–5.69), or at recovery (+4.06 %; 
95 % CI 0.81–8.93). No significant changes in WMSI were observed at any stress levels. GLS and GLSR at rest did not 
improve. The maximal exercise capacity estimated by metabolic equivalents was not affected by liraglutide.
Conclusion: In conclusion, liraglutide did not improve the systolic function of the left ventricle during DSE or the 
exercise capacity in patients with T2D and stable CAD.
Clinical Trial Registration http://www.clinicaltrials.gov (unique identifier: NCT01595789)
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Background
Type 2 diabetes (T2D) and coronary artery disease (CAD) 
increases the risk of cardiac dysfunction [1]. Subclinical 
LV dysfunction is present in patients with T2D and is 
attributable to factors such as insulin resistance, micro-
vascular disease and cardiac autonomic dysfunction [2]. 
Despite improved glycemic control in patients with T2D 
treated with glucose lowering agents, there is little evi-
dence from clinical trials of reduced risk of heart failure, 
although the EMPA-REG Outcome Study recently has 
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challenged this view [3]. Some glucose lowering agents 
have been associated with an increased risk of hospitali-
zation for heart failure [4]. Consequently, investigations 
of safe anti-glycemic treatments that may improve or 
preserve cardiac function in patients with type T2D and 
CAD are warranted.
The diabetic heart is characterized by increased fatty 
acid (FA) oxidation and reduced glucose uptake resulting 
in a decreased cardiac efficiency as more oxygen is needed 
to generate ATP. This feature is undesirable in the ischemic 
setting where oxygen supply is limited [5]. The incretin 
hormone, glucagon-like peptide-1 (GLP-1), has shown 
to increase myocardial glucose uptake [6]. This observa-
tion has facilitated clinical studies where GLP-1 infusion 
improved cardiac function in patients with CAD and 
reduced [7, 8] or preserved systolic function [9]. However, 
the use of short-term continuous infusion of GLP-1 in 
these studies limits the clinical application of the findings. 
Thus, the effect on systolic function using a GLP-1 recep-
tor agonist suitable for long-term treatment was evident. 
In particularly, this may be important in patients with T2D 
and CAD as it may affect the long term prognosis.
The long lasting GLP-1 RA liraglutide with a half-life of 
13  h has in combination with the biguanide metformin 
shown to be a safe treatment option in patients with T2D 
[10]. We hypothesized that treatment with liraglutide 
added to a backbone therapy of metformin in patients 
with CAD and T2D would improve the systolic function 
of the left ventricle during dobutamine stress.
Methods
This is a randomized, double-blind, placebo-controlled 
12 plus 12 week crossover study with a 2 week washout 
period. The outline of the trial visits, the inclusion crite-
ria and the exclusion criteria have all been described in 
detail previously [11]. In short, patients with stable CAD, 
left ventricular ejection fraction (LVEF) >40 % and newly 
diagnosed T2D within 24  months were identified using 
patient files from selected hospitals in Copenhagen area 
and invited consecutively to participate in this study. 
Patients were enrolled from May 2012 until final data 
collection in October 2014. The subjects underwent dob-
utamine stress echocardiography, blood tests, anthropo-
metric measurements, blood pressure measurements, 
and an exercise tolerance test at the beginning and end 
of each period (week 0, 12, 14, and 26). The allocation 
sequence was concealed until all subjects had completed 
the study and all the echocardiography analyses had been 
performed.
Primary and secondary endpoints
The primary endpoint was a change in LVEF assessed by 
Simpson’s biplane method at rest and during dobutamine 
stress echocardiography. Secondary endpoints were 
changes in exercise capacity and changes in other echo-
cardiographic measures of systolic function including: 
global longitudinal strain (GLS) at rest, global longitu-
dinal strain rate (GLSR) at rest, and wall motion score 
index (WMSI) at rest and during dobutamine stress 
echocardiography.
Study drug and dosage
Subjects had a minimum 2 week washout period for their 
glucose lowering therapy prior to the first baseline visit. 
The study drugs liraglutide/placebo subcutaneous injec-
tions and metformin tablets were titrated in an identi-
cal manner in both periods: 0.6  mg liraglutide/placebo 
od + 500 mg metformin bid was increased after 14 days 
to 1.2 mg od + (1000 mg + 500 mg) daily and to 1.8 mg 
od + 1000 mg bid after 28 days [11]. Efforts were made 
to give subjects the same dosage of study drug in both 
periods.
Ethics and dissemination
This study was approved by the Regional Committee 
on Biomedical Research Ethics of the Capital Region of 
Denmark and the Danish Medicines Agency. The study 
has been carried out in accordance with the ICH-GCP 
(International Conference on Harmonization-Good Clin-
ical Practice) standards and was monitored by the GCP-
unit for eastern Denmark. Written informed consent was 
obtained from each participant.
Dobutamine stress echocardiography
The details of echocardiography protocol have been 
described previously [11]. In short, two-dimensional 
echocardiography was performed at rest and during 
dobutamine infusion using a M5S transducer (Vivid E9, 
GE Vingmed Ultrasound, Horten, Norway) and analyzed 
off-line (GE EchoPAC V. 112). Dobutamine was adminis-
tered an incremental regimen to reach target HR for each 
stress level [12]. LVEF was calculated using the Simpson 
biplane method [13] from contrast-enhanced images. 
Baseline images were used as reference for each stress 
level and for the examinations in the following visits in 
an attempt to get comparable visualization of the LV. The 
echocardiography examinations were performed by four 
investigators (AS, OWN, OK, and PK). Global longitu-
dinal strain (GLS) and strain rate (GLSR) was assessed 
using 2D speckle tracking and calculated as the average of 
the peak systolic values for the apical 4-chamber, 2-cham-
ber, and long-axis views. Wall motion score (WMS) was 
assessed using a 16-segment model of the left ventricle 
and graded by the following score: 1 = normal or hyper-
kinetic; 2 = hypokinetic; 3 = akinetic; 4 = dyskinetic or 
aneurysmal [13]. Wall motion score index (WMSI) was 
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calculated as the sum of the scores divided by the number 
of segments visualized. An abnormal stress response was 
defined as stress induced regional wall motion abnormal-
ities (RWMA), either because of increased WMS at peak 
stress compared to rest (ischemic response) or because 
of decreased WMS at low stress (biphasic) or peak stress 
(viable). LV mass index (2D method) and relative wall 
thickness (RWT) was calculated as recommended [13]. 
All echocardiography analyses were performed by one 
observer (PK). Consensus for LVEF was achieved by an 
average of the LVEF measurements between two observ-
ers in any questionable cases. WMS assessment was also 
reviewed by one senior cardiologist (AS or OWN). If the 
discrepancy between the observer (PK) and the senior 
cardiologist involved more than one segment classified as 
abnormal or more than two points in total WMS score, 
the images were also assessed by a second senior cardi-
ologist and consensus was obtained.
Cycle ergometer exercise tolerance test
A standard cycle ergometer exercise tolerance test was 
performed with a workload appropriate for each subject: 
a starting work load of 25  W with an increasing work 
load of 25 or 50  W every 2  min. Subjects were encour-
aged to exercise until maximal exhaustion. The maximal 
exercise capacity was expressed as total exercise dura-




Power-calculation has been described previously [11]. 
A post hoc power calculation analysis was added based 
on the actual data. The SD for the difference between 
two values for the measurements in placebo period 
was used. At rest a SD of 5.0 % was observed, and with 
n =  30 patients a paired analysis provided 80  % power 
to detect a minimum detectable difference of 2.7 %. For 
low stress, peak stress and recovery a SD of 6.5, 7.3 and 
9 % was observed and with n = 29, n = 24, and n = 29 
this provided 80 % power to detect difference of 3.5, 4.4 
and 4.9 %, respectively. A dropout rate of approximately 
20  % was estimated. Continuous variables were sum-
marized as the mean ±  SD or medians with interquar-
tile ranges, and categorical variables were summarized 
as percentages. The intention-to-treat (ITT) population 
was defined as subjects who completed minimum one 
measurement series in one period. The per-protocol 
population was defined as subjects who completed both 
measurement series in both intervention periods. A lin-
ear-mixed model with random effects for subjects and 
fixed effects for period and treatment was used in the 
analysis of the treatment effect on the primary endpoint 
in the ITT-population. The paired t test was used to 
compare the treatment effects of liraglutide and placebo 
for the per-protocol population. For non-normally dis-
tributed data Wilcoxon signed-rank test was used. Sub-
group analyses were performed according to baseline 
DSE response. A two-sided p value of less than 0.05 was 
considered statistically significant. Reproducibility for 
LVEF was assessed in four randomly selected patients 
with four levels of stress (baseline, low stress, peak stress 
and recovery), totaling 16 measurements per observer. 
Interobserver variability for three observers (PK, OWN, 
AS) and intraobserver variability for one observer (PK) 
were calculated by obtaining variance estimates using 
two-way and one-way analysis of variance (ANOVA) and 
were expressed as a coefficient of variation (CoV) and a 
coefficient of repeatability (COR) [15, 16]. All statistical 
analyses were performed with Stata 13.1 (StataCorp, TX, 
USA).
Results
In total, 41 patients were randomized and assigned to an 
intervention. Two subjects declined to participate after 
randomization, leaving 39 subjects available for baseline 
visit with 19 subjects receiving liraglutide first and 20 
subjects receiving placebo first. Subsequently, 9 subjects 
discontinued the study due to serious adverse events 
(n = 2), intolerance to medication (n = 3), and other rea-
sons (n = 4). Thus, 30 subjects were available for per pro-
tocol analysis (Fig. 1).
Table 1 shows the baseline characteristics for the study 
population. Subjects had normal LVEF and normal LV 
geometry. Prior to enrolment in the study, 24 patients 
were not receiving diabetes medication and were being 
treated with diet and life style therapy. Fifteen patients 
were on metformin, and one patient was also receiv-
ing sulfonylurea therapy. All subjects had CAD defined 
by one or more of the following conditions: previous 
myocardial infarction (MI) (n  =  23), previous CABG 
(n =  13), previous PCI (n =  25) or stenosis  >50  % of a 
major coronary artery (n = 2) (Table 1).
Effect of liraglutide on systolic function
Table  2 shows the treatment effect of liraglutide and 
placebo on systolic function for patients with a com-
plete measurement series at each stress level. Changes 
in LVEF during liraglutide period were not significantly 
different from changes during placebo period at any 
stress level. No improvement in WMSI at any stress level 
was observed. No significant changes were evident for 
GLS and GLSR. ITT analysis revealed a near-significant 
change in LVEF at recovery (coefficient 4.10, 95  % CI 
0.01–8.20). No significant changes were observed in the 
other stress levels (Additional file 1: Table S1).
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Liraglutide did not affect any significant changes in LV 
end-diastolic and end-systolic volume (Additional file 1: 
Table S2). Nine subjects in the per-protocol population 
had abnormal stress response at baseline and sub-group 
analyses did not reveal any significant changes in LVEF at 
any stress level (Additional file 1: Table S3).
Effect of liraglutide on exercise test performance
Exercise tolerance test results were available for 21 sub-
jects for all 4 visits. No significant differences in the 
maximal achieved METS was observed between the lira-
glutide and placebo treatment period (METS −0.13 ± 0.6 
vs. −0.42 ± 0.87; 95 % CI −0.22 to 0.80; p = 0.244). The 
total exercise time was slightly reduced at the end of both 
treatment periods, but with no difference in the treat-
ment effect (−25 vs. −24 s; p = 0.980, respectively).
Effect of liraglutide on metabolic and hemodynamic 
parameters
Liraglutide induced a significant weight loss (−3.2  kg; 
95 % CI −4.8 to −1.6; p < 0.001), reduction in waist ratio 
(−2.2 cm; 95 % CI −4.1 to −0.3; p = 0.026), and reduc-
tion in HbA1C (−0.4 %; 95 % CI −0.6 to −0.2; p < 0.001) 
in comparison to placebo. No significant changes in 
LDL-cholesterol, triglyceride, HOMA IR, insulin or fast-
ing blood glucose were observed (Table 3).
Systolic and diastolic blood pressure measurements 
at study visits or during dobutamine stress did not 
change significantly; however, a significant increase in 
the resting heart rate was observed (6.2 beats per min-
ute (bpm); 95 % CI 0.8–11.5; p = 0.001). Heart rate was 
also increased after liraglutide treatment at low stress 
(10.3 bpm; 95 % CI 0.2–20.4; p = 0.046) and peak stress 
levels (5.3 bpm; 95 % CI 1.2–9.5; p = 0.014) (Additional 
file 1: Table S4).
Reproducibility
For LVEF measurement the interobserver and intrao-
bserver variability were, SD 3.4 and 2.2  %; CoV 4.4 and 
2.9 %; COR 6.6 and 6.1 %, respectively.
Safety and compliance
The frequency of adverse events was higher in the liraglu-
tide treatment period and was predominantly due to gas-
trointestinal side effects: nausea (20 %), anorexia (13 %), 
and gastroesophageal reflux disease (9 %) (Table 4; Addi-
tional file 1: Table S5). A total of 9 serious adverse events 
(SAE) were observed in the study period (Additional 
Fig. 1 Screening, enrollment, and follow-up of the study population
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file  1: Table S6). Compliance to liraglutide and placebo 
was high, and there was no difference between treatment 
periods (94.4 and 93.6  %; p  =  0.66). No difference in 
compliance to metformin was observed (94.4 and 90.9 %; 
p = 0.07).
Discussion
In this double-blind, placebo controlled study we showed 
that 12  weeks of liraglutide treatment did not improve 
LVEF during dobutamine stress in patients with stable 
CAD, preserved LVEF and newly diagnosed T2D. Fur-
thermore, no significant changes in WMSI or exercise 
capacity were observed. GS and GSR parameters at rest 
did not improve either.
Early studies of GLP-1 infusion were performed in 
patients with heart failure and showed an improvement 
in LVEF after both short term and long term GLP-1 infu-
sion [7, 17]. However, these findings could not be con-
firmed in randomized placebo-controlled studies. Two 
days of GLP-1 infusion did not improve LVEF in non-
diabetic patients with chronic compensated heart fail-
ure [18]. Recently, a randomized study showed no effect 
of 12 weeks of treatment with the GLP-1 RA albiglutide 
on cardiac function in patients with heart failure [19]. 
Although the subjects in the two latter studies did not 
have T2D and had reduced LVEF, the findings are con-
sistent with results in the present study.
In patients with preserved LVEF, GLP-1 infusion dur-
ing coronary artery bypass grafting did not improve post-
operative LVEF in a cohort of diabetic and non-diabetic 
patients [20]. However, 1  week of subcutaneous lira-
glutide treatment after MI in subjects with and without 
diabetes showed an improvement in LVEF at 3  months 
follow-up [21, 22]. In contrast to our study, these stud-
ies were performed in a setting of acute MI and thus 
under stress-induced hyperglycemia and inflammatory 
response, that might be subject to a particular beneficial 
effect of GLP-1 RA treatment [23].
Read et al. [9] performed DSE in 14 subjects with pre-
served left ventricular function awaiting coronary revas-
cularization and showed a significant improvement in 
LVEF at peak stress during GLP-1 infusion and an atten-
uation of post-ischemic dysfunction. Accordingly, we 
would have expected some GLP-1 RA mediated improve-
ment in the systolic parameters in our study cohort 
during DSE. However, in the study by Read et  al. the 
beneficial effect of GLP-1 was predominantly in ischemic 
segments. Our subgroup analysis did not show any dis-
tinct effect on LVEF in subjects with abnormal stress 
Table 1 Baseline characteristics of the study population
Data are expressed as the mean (SD), n (%) or median (quartiles 1–3)
ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor 
blocker, BMI body mass index, bpm beats per minute, CABG coronary artery 
bypass grafting, eGFR estimated glomerular filtration rate, HbA1C glycated 
hemoglobin, HOMA-IR homeostasis model analysis of insulin resistance, MI 
myocardial infarction, LDL low-density lipoprotein, LVEF left ventricular ejection 
fraction, RWT relative wall thickness, PCI percutaneous coronary intervention
Characteristics Total (n = 39)
Clinical characteristics
 Age, years 61.8 (7.6)
 Male sex, n (%) 31 (79)
 Weight, kg 96.9 (17.1)
 BMI, kg/m2 31.6 (4.8)
 Waist, cm 110.4 (11.2)
 Systolic blood pressure, mmHg 139.3 (19.4)
 Diastolic blood pressure, mmHg 80.2 (10.1)
 Heart rate, bpm 71.7 (12.1)
Risk factors
 Smoker, n (%) 14 (36)
 Hypertension, n (%) 29 (74)
Coronary artery disease
 Previous MI, n (%) 23 (59)
 Previous CABG, n (%) 13 (33)
 Previous PCI, n (%) 25 (64)
 Coronary stenosis, medical therapy only, n (%) 2 (5)
Biochemistry
 Fasting blood glucose, mmol/L 6.5 (1.4)
 HbA1C, % 6.4 (0.5)
 LDL-cholesterol, mmol/L 2.3 (0.7)
 eGFR, ml/min 80.5 (11)
 HOMA IR, median (IQR) 4.02 (2.96, 7.49)
 f-Insulin, median (IQR), pmol/L 93 (64, 155)
Medication
 Beta blockers, n (%) 24 (62)
 Calcium antagonists, n (%) 21 (54)
 ACE-I, ARB, n (%) 26 (67)
 Statins, n (%) 37 (95)
 Ivabradine, n (%) 1 (3)
 Diuretics, n (%) 11 (28)
 Nitrate, n (%) 11 (28)
 Aspirin, n (%) 37 (95)
Pre-study diabetes medication
 Biguanide (metformin), n (%) 15 (38)
 Sulfonylurea, n (%) 1 (3)
 Diet and lifestyle therapy only, n (%) 24 (62)
Echocardiographic measures
 LVEF, % 58.9 (7.6)
 LVmass index, g/m2 81.9 (21.4)
 RWT, cm 0.33 (0.09)
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response. Notably, the group accounted for just nine sub-
jects. Our study probably reflects a clinical relevant situ-
ation where most patients with diabetes and CAD have 
undergone revascularization leading to a low frequency 
of abnormal stress response. Although microcircula-
tion may still be compromised in these patients, we did 
not observe any positive effects on LV systolic function 
by liraglutide treatment. Furthermore, dobutamin stress 
Table 2 Effect of liraglutide versus placebo on systolic function at each stress level
Data are expressed as the mean (SD)
N is the number of subjects for each treatment phase with valid measurements in each stress level, GLS global longitudinal strain, GLSR global longitudinal strain rate, 
WMSI wall motion score index, LVEF left ventricular ejection fraction
Before liraglutideAfter liraglutide Before placebo After placebo N Treatment effect Difference (95 % 
CI)
p value
Baseline 12 weeks Baseline 12 weeks Liraglutide Placebo
LVEF, %










75.72 (9.52) 76.92 (9.14) 76.26 (8.72) 76.02 (8.12) 24 0.87 (6.91) −0.25 (7.26) 1.12 (−3.45 to 
5.69)
0.618














1.079 (0.235) 1.052 (0.160) 1.058 (0.149) 1.060 (0.213) 24 −0.03 (0.10) 0.01 (0.08) −0.038 (−0.112 
to 0.035)
0.292








 Rest 0.90 (0.18) 0.91 (0.18) 0.86 (0.17) 0.88 (0.2)18 30 0.01 (0.15) 0.02 (0.14) −0.01 (−0.05 to 
0.08)
0.713
Table 3 Effect of liraglutide versus placebo on anthropometric and biochemical variables
Data are expressed as the mean (SD)
BMI body mass index, HbA1C glycated hemoglobin, LDL low-density lipoprotein, HOMA IR homeostasis model analysis of insulin resistance
Treatment effect Difference 95 % CI p value
Liraglutide Placebo
Weight, kg −4.17 (3.49) −0.98 (2.62) −3.18 (4.31) −4.79 to −1.57 <0.001
Waist, cm −2.80 (4.11) −0.57 (2.52) −2.22 (4.89) −4.16 to −0.29 0.026
BMI, kg/m2 −1.35 (1.10) −0.31 (0.85) −1.04 (1.34) −1.54 to −0.54 <0.001
Systolic blood pressure, mmHg −8.10 (17.27) −3.17 (16.07) −4.93 (23.68) −13.78 to 3.91 0.263
Diastolic blood pressure, mmHg −3.13 (12.11) −3.83 (8.75) 0.70 (17.06) −5.67 to 7.07 0.826
HbA1C, % −0.42 (0.34) −0.04 (0.43) −0.37 (0.54) −0.57 to −0.17 <0.001
LDL-cholesterol, mmol/L −0.25 (0.72) −0.17 (0.63) −0.08 (0.96) −0.47 to 0.30 0.657
HOMA IR, pmol/L −1.35 (3.18) −0.57 (2.41) −0.78 (3.24) −2.01 to 0.45 0.336
Fasting plasma insulin, pmol/L −11.73 (57.54) −1.69 (43.79) −10.04 (68.27) −36.01 to 15.93 0.469
Fasting blood glucose, mmol/L −0.99 (1.11) −0.62 (0.96) −0.36 (1.06) −0.76 to 0.03 0.125
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would increase the myocardial oxygen demand through 
its inotropic and chronotropic effects mediated by myo-
cardial beta-receptors [24]. The combination of the 
increased oxygen demand and the less energy efficient 
FA oxidation, which is increased in the diabetic heart, is 
expected to reduce the cardiac efficiency [5]. Thus, a shift 
towards increased glucose-oxidation mediated by liraglu-
tide would potentially improve LV performance. How-
ever, this was not evident in our study.
Interestingly, the largest improvement in LVEF in the 
present study was observed during recovery period after 
peak stress. In addition to increased myocardial glucose 
uptake, GLP-1 may activate pro-survival intracellular 
signaling pathways that may have beneficial effects in 
particularly in post-ischemic myocardial function [25]. 
Furthermore, additional pathways such as cyclic adeno-
sine monophosphate mediated activation of protein 
kinase A [26] may also be involved in the infarct-size 
reducing effects of GLP–1 RAs as demonstrated in stud-
ies using exenatide infusion [27, 28].
GLS assessed by 2D speckle-tracking allows for an 
angle-independent assessment of systolic function and 
has shown to be a very sensitive marker for early detec-
tion of myocardial disease [29]. Despite preserved LVEF 
our study population had a reduced GLS compared to 
a previous suggested reference value of −19.7  % thus 
reflecting a subclinical systolic dysfunction that charac-
terizes the T2D and CAD population [30, 31].
We observed a significant reduction in HbA1C and a 
net body weight loss that was comparable to what has 
been reported in previous studies on liraglutide [32]. It 
could be contemplated that the newly diagnosed T2D 
in our study population may have limited the potential 
effect of GLP-1 agonism on the cardiac function. How-
ever, previous studies have shown improvement in car-
diac function in cohorts consisting of both T2D and 
non-T2D patients [7, 9, 21]. Furthermore, myocardial 
insulin resistance have shown to be an inherent feature of 
both CAD and T2D [33], and thus providing a treatment 
target for liraglutide.
GLP-1 infusion has shown to improve remodeling in 
pre-clinical studies [34]. This was also demonstrated in 
a retrospective study assessing remodeling by cardiac 
MRI in patients treated with liraglutide [35]. However, 
consistent with our study, no improvement in LVEF was 
observed after 6 months.
Previous reporting of elevated heart rate associated 
with liraglutide treatment was also observed in our study 
[36]. In particularly, this has been of concern due to the 
association between elevated HR and increased risk of 
LV dysfunction and heart failure [37]. Despite a signifi-
cant increased resting HR during 12 weeks of liraglutide 
treatment, we did not find any significant worsening of 
LV function at rest or during DSE. Interestingly, HR was 
also increased during low-stress and peak-stress stages of 
DSE after liraglutide. The chronotropic effect of GLP-1 
RAs is believed to be mediated via GLP-1 receptors 
located to the sinoatrial node [38]. However, studies have 
suggested that GLP-1 may exhibit an inhibitory effect on 
sympathovagal balance as well [39].
Exercise capacity is an independent predictor of all-
cause mortality and CV-mortality [40]. An improvement 
in exercise capacity assessed by a 6  min walk test was 
found after 5  weeks of GLP-1 infusion in patients with 
heart failure [8], but could not be confirmed in a rand-
omized study where cardiopulmonary exercise testing 
was performed after 48  h GLP-1 infusion [18] or after 
12  weeks of albiglutide treatment [19]. Despite the sig-
nificant weight loss during liraglutide treatment in our 
study, we did not observe any improvement in exercise 
capacity assessed by METS or the total exercise time.
Safety and adverse events
In general the study drugs were well-tolerated as only 
three subjects discontinued the study due to intolerance 
to medication. Two patients experienced MI during the 
study and were subsequently withdrawn from the study. 
Both of these events were deemed by the investigators 
to be unrelated to treatment. One patient experienced 
an allergic reaction during the DSE at baseline visit. This 
patient subsequently underwent ergometer stress echo-
cardiography without contrast during all four visits.
Strengths and limitations
Although comparable DSE scans were aimed for at all 
four levels of stress and between visits by using refer-
ence images from the baseline visit, we cannot exclude 
that some differences in the scanning positions may have 
contributed to the overall variation. However, the use of 
Table 4 Adverse events in each period by event category
Data are expressed as n (%)






Abnormal blood test 4 (4.4) 1 (2.6) 1 (7.7)
Cardiac 8 (8.8) 6 (15.8) 4 (30.8)
Gastrointestinal 56 (61.5) 15 (39.5) 2 (15.4)
Infection 4 (4.4) 5 (13.2) 3 (23.1)
Muscle 0 (0) 1 (2.6) 1 (7.7)
Neurological 11 (12.1) 6 (15.8) 2 (15.4)
Renal, urine 1 (1.1) 1 (2.6) 0 (0)
Skin 3 (3.3) 1 (2.6) 0 (0)
Vascular 2 (2.2) 2 (5.3) 0 (0)
Other 2 (2.2) 0 (0) 0 (0)
Total adverse events 91 38 13
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contrast-enhanced 2D echo has shown to increase the 
accuracy and reproducibility echocardiographic exami-
nations [41]. The homogeneity of our study populations 
limits the application of our results to other patient 
groups such as patients with heart failure or patients with 
longer duration of diabetes and poor glycemic control.
Perspectives
The presence of subclinical LV dysfunction and increased 
risk of heart failure in subjects with T2D and CAD neces-
sities exploration of glucose lowering medication that 
may improve and prevent further deterioration of cardiac 
function. In this context, an understanding of how GLP-1 
RAs affect the myocardial function during conditions of 
myocardial stress is of great importance. Any improve-
ment in systolic function during stress may prevent the 
long-term deterioration of LV performance and progres-
sion to heart failure. Although, no significant improve-
ment in systolic function was observed in our study, 
we did not observe any deterioration in cardiac func-
tion. Thus, liraglutide may be a safe treatment option in 
patients with cardiac risk factors and preserved LVEF. 
The recently published LEADER trial showed improved 
effect on CV mortality after liraglutide treatment [42]. 
Notably, no increased risk of hospitalization for heart 
failure was observed. We believe that our study adds to 
the further understanding of the results from the various 
long-term GLP-1 RA trials.
Conclusions
In patient with preserved LVEF, T2D, and stable CAD, 
the addition of liraglutide to the backbone therapy of 
metformin did not improve the systolic function of the 
LV or the exercise capacity.
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